These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 24866832

  • 1. Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.
    Kim HD, Kang KD, Choi KS, Rhee MR, Lee SJ.
    Acta Ophthalmol; 2014 Nov; 92(7):e589-90. PubMed ID: 24866832
    [No Abstract] [Full Text] [Related]

  • 2. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S, Rush R, Natarajan S, Gillies M.
    Clin Exp Ophthalmol; 2011 Nov; 39(7):673-81. PubMed ID: 22452685
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Kumar V, Ghosh B, Raina UK, Goel N.
    Am J Ophthalmol; 2008 Dec; 146(6):974; author reply 974-5. PubMed ID: 19027427
    [No Abstract] [Full Text] [Related]

  • 8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X, Li J, Hu X, Yu S, Pan J, Tang S.
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.
    Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K.
    Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
    Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA.
    Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
    Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R.
    Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion.
    Moon J, Kim M, Sagong M.
    Eye (Lond); 2016 Aug; 30(8):1084-90. PubMed ID: 27229707
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
    Akinci A, Muftuoglu O, Altınsoy A, Ozkılıc E.
    Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
    [Abstract] [Full Text] [Related]

  • 19. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
    Sonoda Y, Arimura N, Shimura M, Sakamoto T.
    Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.